Hirokawa Makoto, Sawada Ken-ichi, Fujishima Naohito, Kawano Fumio, Kimura Akiro, Watanabe Takashi, Arai Ayako, Matsui Toshimitsu, Nakao Shinji, Urabe Akio, Omine Mitsuhiro, Ozawa Keiya
Division of Hematology and Oncology, Department of Medicine, Akita University School of Medicine, Akita, Japan.
Am J Hematol. 2009 Mar;84(3):144-8. doi: 10.1002/ajh.21354.
Pure red cell aplasia (PRCA) has been reported in association with lymphoma as one of the autoimmune diseases seen during the course of lymphoid malignancies. However, the relation of PRCA with the underlying lymphomas remains unclear. The aim of this study was to clarify the histologic subtypes of lymphomas, the chronological sequence of anemia and lymphoma, and the response to treatment. We conducted a nationwide survey in Japan. From a cohort of 185 PRCA patients, 8 patients with lymphoma were evaluated. Histologic subtypes varied and the lymphoma was of the B-cell type in four cases and of the T-cell type in four. Four patients simultaneously developed PRCA and lymphoma. Three patients developed PRCA following lymphoma, two of whom developed anemia during remission of lymphoma. PRCA preceded lymphoma in one patient. Effective chemotherapy was associated with remission of anemia in concurrent lymphoma and PRCA. Overall, anemia responded to chemotherapy and/or immunosuppressive therapy in seven patients. In four responding patients, PRCA remained in durable remission without maintenance immunosuppressive therapy, which is different from a recurrent feature of idiopathic PRCA. We suggest that the mechanism of lymphoma-associated PRCA is heterogeneous and that durable maintenance-free remission of anemia can be obtained in some patients.
纯红细胞再生障碍性贫血(PRCA)已被报道与淋巴瘤相关,是淋巴系统恶性肿瘤病程中出现的自身免疫性疾病之一。然而,PRCA与潜在淋巴瘤之间的关系仍不明确。本研究的目的是明确淋巴瘤的组织学亚型、贫血与淋巴瘤的先后顺序以及对治疗的反应。我们在日本进行了一项全国性调查。在185例PRCA患者队列中,对8例合并淋巴瘤的患者进行了评估。组织学亚型各异,其中4例淋巴瘤为B细胞型,4例为T细胞型。4例患者同时发生PRCA和淋巴瘤。3例患者在淋巴瘤发生后出现PRCA,其中2例在淋巴瘤缓解期发生贫血。1例患者PRCA先于淋巴瘤出现。有效的化疗与同时合并淋巴瘤和PRCA患者的贫血缓解相关。总体而言,7例患者的贫血对化疗和/或免疫抑制治疗有反应。在4例有反应的患者中,PRCA在未进行维持性免疫抑制治疗的情况下持续缓解,这与特发性PRCA的复发特征不同。我们认为淋巴瘤相关PRCA的机制是异质性的,并且一些患者可以获得贫血的持久无维持缓解。